The MNI forms promising Open Science partnership with Takeda
(McGill University) A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.
Inclusion Body Myopathy (IBM) associated with Paget's disease of the bone (PDB) and/or frontotemporal dementia (FTD) or Multisystem Proteinopathy (OMIM 167320) or more commonly called IBMPFD or VCP disease, was first reported by Kimonis et al. (2000) . VCP disease comprises other less common phenotypes including amyotrophic lateral sclerosis (ALS), Parkinson's disease, cardiomyopathy, sensory motor axonal neuropathy, and sphincter disturbance [2 –6]. IBMPFD is an underdiagnosed disease that has been reported in greater than 100 families worldwide, but is more commonly found in the United States and Europe.
Many thanks for forwarding the letter from T. Kawada  addressing our manuscript on the lack of association between ADHD and ALS in this journal . In principle, the author points out that this topic would deserve further epidemiological studies to come to a more substantiated conclusion. Pathophysiological considerations alone would not suffice to exclude a causal relationship between these two neurodevelopmental and neurodegenerative, respectively, conditions.
Adding rasagiline to riluzole did not extend survival, the primary endpoint, in amyotrophic lateral sclerosis, but post hoc analysis suggests it may benefit those deemed'fast progressors. 'Medscape Medical News
(University of California - Riverside) Maurizio Pellecchia at the University of California, Riverside has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. The first grant from the US-Egypt Science and Technology Joint Fund of the National Academy of Sciences, Engineering, and Medicine totals $190,000 for two years. The second is a nearly $2.3 million, five-year grant from the National Institute of Neurological Disorders and Stroke.
Publication date: Available online 20 June 2018 Source:Molecular Immunology Author(s): Anne-Lene Kjældgaard, Katrine Pilely, Karsten Skovgaard Olsen, Stephen Wørlich Pedersen, Anne Øberg Lauritsen, Kirsten Møller, Peter Garred Amyotrophic lateral sclerosis (ALS) is a devastating, neurodegenerative motor neuron disease. The aetiology of ALS remains an enigma which hinders the design of an effective treatment to prevent, postpone, or reverse the pathophysiological changes occurring during the aggressive progression of this disease. During the last decade, basic research within the innate immune sy...
Ebel et al. evaluated the association between attention-deficit/hyperactivity disorder (ADHD) and amyotrophic lateral sclerosis (ALS) . Sociodemographic factors and physical activities were also considered in the analysis. The authors cited a paper, presenting the hypothesis that there was a pathophysiological link between ADHD and ALS , however ALS patients reported a lower prevalence of childhood ADHD and there was no evidence that ADHD had been more common in ALS patients. I have 2 concerns about this study.
(MacDougall Biomedical Communications, Inc.) Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS) in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Xueping Chen, Qian-Qian Wei, Yongping Chen, Bei Cao, RuWei Ou, Yanbing Hou, Xiaoqin Yuan, Lingyu Zhang, Hui Liu, Huifang Shang
Publication date: Available online 18 June 2018 Source:Molecular and Cellular Neuroscience Author(s): Rachit Bakshi, Yuehang Xu, Kaly A. Mueller, Xiqun Chen, Eric Granucci, Sabrina Paganoni, Ghazaleh Sadri-Vakili, Michael A. Schwarzschild Dominant mutations in an antioxidant enzyme superoxide dismutase-1 (SOD1) cause amyotrophic lateral sclerosis (ALS), an adult-onset neurodegenerative disease characterized by loss of motor neurons. Oxidative stress has also been linked to many of the neurodegenerative diseases and is likely a central mechanism of motor neuron death in ALS. Astrocytes derived from mutant SOD1 G93A mouse m...
Abstract Cannabinoid receptor CB2 (CB2R) is upregulated on activated microglia and astrocytes in the brain under inflammatory conditions and plays important roles in many neurological diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke. The advent of positron emission tomography (PET) using CB2R radiotracers has enabled the visualization of CB2R distribution in vivo in animal models of central nervous system inflammation, however translation to humans has been less successful. Several novel CB2R radiotracers have been developed and evaluated to quantify microglial activation. ...